

Company name-DIO TREE LTD----- * Website---www.dio-tree.com-----

----- * CEO name—Dr. Sarit Batsir-----* CATEGORY:

Biotech/Pharma Select one SESSION per abstract from the list below * “Redefining the Fight Against Cancer: New Targets, New Modalities.” Executive Summary / Investment Rational Dio-Tree develops a first-in-class therapy targeting DIO3 to treat ovarian cancer. Large unmet need with poor survival rates. Preclinical stage with promising data. Seeking \$2M to reach first-in-human trials. Led by experienced CEO and scientific founder, with clinical collaborations and strong translational focus. Core Technology Proprietary targeting of DIO3, a novel enzyme driving tumor progression. Unique mechanism restoring local thyroid hormone activity in tumors. Differentiated, first-in-class approach with potential broad oncology applications. Strong IP position and biomarker-driven strategy enhance precision and clinical success probability. Product Profile/Pipeline Lead program targets ovarian cancer, currently in preclinical validation. Demonstrated efficacy in early models. Pipeline expansion potential into additional solid tumors. Key milestones: IND-enabling studies and clinical entry. Open to pharma partnerships for co-development and clinical advancement. Business Strategy Advance lead asset to clinical proof-of-concept, then partner with pharma. Short-term value via milestones and collaborations; long-term via licensing or acquisition. Platform expansion enables multiple indications, increasing value. Focus on capital-efficient development and strategic partnerships. What's Next? Complete preclinical studies and initiate first-in-human trial. Expand scientific and clinical team. Secure \$2M funding round. Strengthen IP and regulatory pathway. Pursue strategic partnerships to accelerate development and validate clinical potential.